keyword
MENU ▼
Read by QxMD icon Read
search

Total PSA Free PSA

keyword
https://www.readbyqxmd.com/read/28919294/studying-the-efficacy-of-escalated-dose-conformal-radiation-therapy-in-prostate-carcinoma-pakistan-experience
#1
Asad Zamir, Ahmad Farooq, Hasan Nisar, Ismat Fatima, Irfan Ullah Khan, Misbah Masood, Abubaker Shahid
BACKGROUND: Our objective in this study was to evaluate the role and benefits in terms of local toxicity and biochemical disease-free survival (bDFS) following escalated-dose conformal radiation therapy in prostate adenocarcinoma. METHODS: The study population was composed of 53 patients with histologically proven T1b-T4, NO, MO prostate adenocarcinoma, having any Gleason score with prostate-specific antigen (PSA) of less than 50 ng/mL at diagnosis, given escalated dose EBRT (74 Gy) during the period between January 2011 and December 2013, retrospectively and evaluated for a period of 2 years post-radiation...
September 14, 2017: Journal of the Chinese Medical Association: JCMA
https://www.readbyqxmd.com/read/28910345/circulating-mrnas-and-mirnas-as-candidate-markers-for-the-diagnosis-and-prognosis-of-prostate-cancer
#2
Marilesia Ferreira de Souza, Hellen Kuasne, Mateus de Camargo Barros-Filho, Heloísa Lizotti Cilião, Fabio Albuquerque Marchi, Paulo Emilio Fuganti, Alexandre Rossi Paschoal, Silvia Regina Rogatto, Ilce Mara de Syllos Cólus
Circulating nucleic acids are found in free form in body fluids and may serve as minimally invasive tools for cancer diagnosis and prognosis. Only a few studies have investigated the potential application of circulating mRNAs and microRNAs (miRNAs) in prostate cancer (PCa). The Cancer Genome Atlas (TCGA) database was used for an in silico analysis to identify circulating mRNA and miRNA as potential markers of PCa. A total of 2,267 genes and 49 miRNAs were differentially expressed between normal and tumor samples...
2017: PloS One
https://www.readbyqxmd.com/read/28903426/the-prognostic-implication-of-intraductal-carcinoma-of-the-prostate-in-metastatic-castration-resistant-prostate-cancer-and-its-potential-predictive-value-in-those-treated-with-docetaxel-or-abiraterone-as-first-line-therapy
#3
Jinge Zhao, Pengfei Shen, Guangxi Sun, Ni Chen, Jiandong Liu, Xin Tang, Rui Huang, Diming Cai, Jing Gong, Xingming Zhang, Zhibin Chen, Xiang Li, Qiang Wei, Peng Zhang, Zhenhua Liu, Jiyan Liu, Hao Zeng
Intraductal carcinoma of the prostate (IDC-P) is recognized as a newly pathological entity in 2016 WHO classification. It's role in metastatic castration-resistant prostate cancer (CRPC) remains obscure. We aimed to explore the association of IDC-P with clinical outcome and to further identify its potential predictive role in making first-line treatment decisions for mCRPC. We retrospectively analyzed data of 131 mCRPC patients. IDC-P was diagnosed by re-biopsy at the time of mCRPC. Among total patients, 45 and 41 received abiraterone or docetaxel as first-line therapies, respectively...
August 15, 2017: Oncotarget
https://www.readbyqxmd.com/read/28882738/testosterone-reduction-of%C3%A2-%C3%A2-480-ng-dl-predicts-favorable-prognosis-of-japanese-men-with-advanced-prostate-cancer-treated-with-androgen-deprivation-therapy
#4
Satoshi Yamamoto, Shinichi Sakamoto, Xu Minhui, Takaaki Tamura, Kotaro Otsuka, Kodai Sato, Marghulan Maimaiti, Shuhei Kamada, Akinori Takei, Miki Fuse, Kouji Kawamura, Takashi Imamoto, Akira Komiya, Koichiro Akakura, Tomohiko Ichikawa
INTRODUCTION: Reductions in testosterone concentration play a significant role in the treatment of prostate cancer. We studied the role of testosterone as a prognostic marker for advanced prostate cancer (stage C or higher) treated with primary androgen-deprivation therapy (ADT). PATIENTS AND METHODS: A total of 348 patients were treated using ADT as first-line therapy for prostate cancer at Chiba University Hospital between 1999 and 2016. Of these, 222 patients with advanced prostate cancer (stage C or higher) were enrolled onto this study...
August 3, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28864928/effects-of-cholesterol-c-reactive-protein-and-interleukin-6-on-prostate-cancer-risk-in-a-population-of-african-ancestry
#5
Marshall K Tulloch-Reid, Norma McFarlane-Anderson, Franklyn I Bennett, William D Aiken, Maria D Jackson
PURPOSE: To investigate the association between serum cholesterol and prostate cancer and whether any effect may be mediated through inflammatory markers. METHODS: Data from a case-control study of 40-80 years old Jamaican male patients (229 cases; 252 controls) were used. Cases had incident histologically-confirmed prostate cancer and controls were men with normal digital rectal examination and prostate-specific antigen (PSA) < 4 μg/L or free: total PSA > 0...
September 1, 2017: Cancer Causes & Control: CCC
https://www.readbyqxmd.com/read/28861300/low-free-and-bioavailable-testosterone-levels-may-predict-pathologically-proven-high-risk-prostate-cancer-a-prospective-clinical-trial
#6
Göksel Bayar, Hakan Şirin, Mustafa Aydın, Ayşim Özağarı, Orhan Tanrıverdi, Mustafa Kadıhasanoğlu, Muammer Kendirci
OBJECTIVE: To determine the predictive value of free and bioavailable testosterone levels on the detection of high-grade prostate cancer proven by histopathological examination of transrectal prostate biopsy specimens. MATERIAL AND METHODS: A total of 405 patients who underwent transrectal prostate biopsy due to high prostatic specific antigen (PSA) (>2.5 ng/mL) and/or abnormal findings at digital rectal examination were included in this study. Blood free and bioavailable testosterone levels were calculated by the formula recommended by International Society for the Study of the Aging Male (ISSAM)...
September 2017: Turkish Journal of Urology
https://www.readbyqxmd.com/read/28844821/low-dose-rate-prostate-brachytherapy-4-8%C3%A2-week-postimplant-prostate-specific-antigen-a-novel-predictor-of-biochemical-failure-free-survival
#7
Cameron M Callaghan, Lin Wang, Abhishek Alluri, Andrew Lauve, Cynthia Boyer, William Russell
PURPOSE: The purpose of this study was to determine the relationship between patient, disease, and treatment variables and biochemical failure-free survival (bFFS) following low-dose-rate prostate brachytherapy (LDR-BT). METHODS AND MATERIALS: Data from 624 consecutive patients who received LDR-BT for localized prostate cancer between 2002 and 2012 at a single institution were collected for various patient, disease, and treatment characteristics including a 4-8 week postimplant PSA (4-8wkPSA)...
August 24, 2017: Brachytherapy
https://www.readbyqxmd.com/read/28841855/comparison-of-psa-value-at-last-follow-up-of-patients-who-underwent-low-dose-rate-brachytherapy-and-intensity-modulated-radiation-therapy-for-prostate-cancer
#8
Nobumichi Tanaka, Isao Asakawa, Yasushi Nakai, Makito Miyake, Satoshi Anai, Tomomi Fujii, Masatoshi Hasegawa, Noboru Konishi, Kiyohide Fujimoto
BACKGROUND: To compare the PSA value at the last follow-up of patients who underwent prostate low-dose rate brachytherapy (LDR-BT) with that of patients who underwent intensity-modulated radiation therapy (IMRT). METHODS: A total of 610 prostate cancer patients (cT1c-3bN0M0) were enrolled, and 445 of them underwent LDR-BT, while 165 received IMRT (74-76 Gy). The median follow-up period of these two groups was 75 months (LDR-BT) and 78 months (IMRT), respectively...
August 25, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28834167/feasibility-and-safety-of-focal-irreversible-electroporation-as-salvage-treatment-for-localized-radio-recurrent-prostate-cancer
#9
Matthijs J Scheltema, Willemien van den Bos, Amila R Siriwardana, Anton M F Kalsbeek, James E Thompson, Francis Ting, Maret Böhm, Anne-Maree Haynes, Ron Shnier, Warick Delprado, Phillip D Stricker
OBJECTIVES: To evaluate the feasibility, safety, early quality of life (QoL) and oncological outcomes of salvage focal irreversible electroporation (IRE) for radio-recurrent prostate cancer (PCa). PATIENTS AND METHODS: Patients with localized, radio-recurrent PCa without evidence of metastatic or nodal disease were offered focal IRE following the consensus guidelines. Patients with a minimum follow-up of 6 months were eligible for analysis. Adverse events were monitored using the NCI Common Terminology Criteria for Adverse Events (CTCAE version 4...
August 21, 2017: BJU International
https://www.readbyqxmd.com/read/28829451/single-step-homogeneous-immunoassay-for-detecting-prostate-specific-antigen-using-dual-color-light-scattering-of-metal-nanoparticles
#10
Stéphanie Vial, Jérôme Wenger
Conventional sandwich-type immunoassays are widely used for protein biomarker detection, yet their workflows are challenged by the need for multiple incubation steps separated by washing cycles. Conducting these immunoassays is thus rather time-consuming and labor-intensive. Moreover, the limited sensitivity around 0.1 ng mL(-1) is challenging the monitoring of cancer recurrence, for instance after radical prostatectomy in the case of prostate cancer. Here, we report a single-step homogeneous immunoassay using dual-color light scattering of metal nanoparticles...
August 22, 2017: Analyst
https://www.readbyqxmd.com/read/28826931/comparison-of-sequential-treatment-with-androgen-receptor-targeted-agent-followed-by%C3%A2-another-androgen-receptor-targeted-agent-versus-androgen-receptor-targeted-agent-followed-by-docetaxel-in-chemotherapy-naive-patients-with-metastatic-castration-resistant
#11
Nobuaki Matsubara, Yoko Yamada, Ken-Ichi Tabata, Takefumi Satoh, Naoto Kamiya, Hiroyoshi Suzuki, Takashi Kawahara, Hiroji Uemura, Akihiro Yano, Satoru Kawakami, Masafumi Otsuka, Satoshi Fukasawa
BACKGROUND: An important clinical question of great interest to clinicians is how to best sequence androgen receptor targeted agents (ARTAs) and chemotherapy for metastatic castration-resistant prostate cancer (mCRPC), but the answer is still unclear. MATERIALS AND METHODS: To evaluate and compare the clinical outcomes of ARTA and docetaxel (DTX) as second-line treatment in the post first-line ARTA, we conducted a retrospective analysis of chemotherapy-naive mCRPC patients who had received sequential treatment with ARTA followed by another ARTA (ARTA-ARTA) or ARTA followed by DTX (ARTA-DTX)...
July 26, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28811062/validation-of-the-prostate-health-index-in-a-predictive-model-of-prostate-cancer
#12
A Sanchís-Bonet, M Barrionuevo-González, A M Bajo-Chueca, L Pulido-Fonseca, L E Ortega-Polledo, J C Tamayo-Ruiz, M Sánchez-Chapado
OBJECTIVES: To validate and analyse the clinical usefulness of a predictive model of prostate cancer that incorporates the biomarker «[-2] pro prostate-specific antigen» using the prostate health index (PHI) in decision making for performing prostate biopsies. MATERIAL AND METHODS: We isolated serum from 197 men with an indication for prostate biopsy to determine the total prostate-specific antigen (tPSA), the free PSA fraction (fPSA) and the [-2] proPSA (p2PSA)...
August 12, 2017: Actas Urologicas Españolas
https://www.readbyqxmd.com/read/28804579/validity-of-prostate-health-index-and-percentage-of-2-pro-prostate-specific-antigen-as-novel-biomarkers-in-the-diagnosis-of-prostate-cancer-omani-tertiary-hospitals-experience
#13
Safana S Al Saidi, Nafila B Al Riyami, Mohammed S Al Marhoon, Mohammed S Al Saraf, Salim S Al Busaidi, Riad Bayoumi, Waad-Allah S Mula-Abed
OBJECTIVES: Prostate cancer is the leading cancer in older men. The Ministry of Health Oman Cancer Incidence Registry 2013 lists cancer of the prostate as the first most common cancer in males. Therefore, early detection is important and prostate-specific antigen (PSA) is widely used as an established laboratory test. However, despite its wide use, its value in screening, particularly in asymptomatic males, is controversial when considering the risks and benefits of early detection. METHODS: This prospective, observational study included 136 males (67...
July 2017: Oman Medical Journal
https://www.readbyqxmd.com/read/28801291/-value-of-pi-rads-v2-scores-combined-with-prostate-specific-antigen-in-diagnosis-of-peripheral-zone-prostate-cancer-a-logistic-regression-analysis
#14
Li-Zhi Lei, Yi-Kai Xu, Mei-Rong Hou, Meng-Qi He
OBJECTIVE: To assess the value of Prostate Imaging and Reporting and Data System: Version 2 (PI-RADS v2) combined with prostate specific antigen (PSA) in the diagnosis of peripheral zone (PZ) prostate cancer (PCa). METHODS: The preoperative magnetic resonance imaging and PSA data were ananlyzed for 69 patients with pathologically confirmed PCa and 109 non-PCa patients. PI-RADS v2 scores (1-5) was used to evaluate the risk of PZ PCa. The total PSA (tPSA) level, free to total PSA ratio (f/t PSA), PSA density (PSAD), PZ-PSAD and PI-RADS v2 scores were compared between the PCa and non-PCa patients...
August 20, 2017: Nan Fang Yi Ke da Xue Xue Bao, Journal of Southern Medical University
https://www.readbyqxmd.com/read/28791252/prostate-specific-antigen-5-years-following-stereotactic-body-radiation-therapy-for-low-and-intermediate-risk-prostate-cancer-an-ablative-procedure
#15
Shaan Kataria, Harsha Koneru, Shan Guleria, Malika Danner, Marilyn Ayoob, Thomas Yung, Siyuan Lei, Brian T Collins, Simeng Suy, John H Lynch, Thomas Kole, Sean P Collins
BACKGROUND: Our previous work on early PSA kinetics following prostate stereotactic body radiation therapy (SBRT) demonstrated that an initial rapid and then slow PSA decline may result in very low PSA nadirs. This retrospective study sought to evaluate the PSA nadir 5 years following SBRT for low- and intermediate-risk prostate cancer (PCa). METHODS: 65 low- and 80 intermediate-risk PCa patients were treated definitively with SBRT to 35-37.5 Gy in 5 fractions at Georgetown University Hospital between January 2008 and October 2011...
2017: Frontiers in Oncology
https://www.readbyqxmd.com/read/28781111/creation-and-internal-validation-of-a-biopsy-avoidance-prediction-tool-to-aid-in-the-choice-of-diagnostic-approach-in-patients-with-prostate-cancer-suspicion
#16
Bimal Bhindi, Haiyan Jiang, Cedric Poyet, Thomas Hermanns, Robert J Hamilton, Kathy Li, Ants Toi, Antonio Finelli, Alexandre R Zlotta, Theodorus H van der Kwast, Andrew Evans, Neil E Fleshner, Girish S Kulkarni
INTRODUCTION: To reduce unnecessary prostate biopsies while using novel tests judiciously, we created a tool to predict the probability of clinically significant prostate cancer (CSPC) vs. low-risk prostate cancer or negative biopsy (i.e., when intervention is likely not needed) among men undergoing initial or repeat biopsy. METHODS: Separate models were created for men undergoing initial and repeat biopsy, identified from our institutional biopsy database and the placebo arm of the REDUCE trial, respectively, to predict the presence of CSPC (Gleason≥7 or>33% of cores involved)...
August 3, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28770408/phase-ii-study-of-radium-223-dichloride-in-japanese-patients-with-symptomatic-castration-resistant-prostate-cancer
#17
Nobuaki Matsubara, Satsohi Nagamori, Yoshiaki Wakumoto, Hirotsugu Uemura, Go Kimura, Akira Yokomizo, Hiroaki Kikukawa, Atsushi Mizokami, Takeo Kosaka, Naoya Masumori, Yoshihide Kawasaki, Junji Yonese, Yasutomo Nasu, Satoshi Fukasawa, Takayuki Sugiyama, Seigo Kinuya, Makoto Hosono, Iku Yamaguchi, Hirokazu Tsutsui, Hiroji Uemura
BACKGROUND: Radium-223 dichloride (radium-223) is the first targeted alpha therapy approved for the treatment of castration-resistant prostate cancer (CRPC) with bone metastases. This study investigated the efficacy and safety of radium-223 in Japanese patients with symptomatic CRPC and bone metastases. METHODS: In this open-label, multicenter, phase II study, patients with progressive, symptomatic CRPC and bone metastases were treated with radium-223 (55 kBq/kg, intravenously) in a 4-week cycle for six cycles...
August 2, 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28765515/the-prognostic-implication-of-intraductal-carcinoma-of-the-prostate-in-metastatic-castration-resistant-prostate-cancer-and-its-potential-predictive-value-in-those-treated-with-docetaxel-or-abiraterone-as-first-line-therapy
#18
Jinge Zhao, Pengfei Shen, Guangxi Sun, Ni Chen, Jiandong Liu, Xin Tang, Rui Huang, Diming Cai, Jing Gong, Xingming Zhang, Zhibin Chen, Xiang Li, Qiang Wei, Peng Zhang, Zhenhua Liu, Jiyan Liu, Hao Zeng
Intraductal carcinoma of the prostate (IDC-P) is recognized as a newly pathological entity in 2016 WHO classification. It's role in metastatic castration-resistant prostate cancer (CRPC) remains obscure. We aimed to explore the association of IDC-P with clinical outcome and to further identify its potential predictive role in making first-line treatment decisions for mCRPC. We retrospectively analyzed data of 131 mCRPC patients. IDC-P was diagnosed by re-biopsy at the time of mCRPC. Among total patients, 45 and 41 received abiraterone or docetaxel as first-line therapies, respectively...
July 24, 2017: Oncotarget
https://www.readbyqxmd.com/read/28753827/the-cpc-risk-calculator-a-new-app-to-predict-prostate-specific-antigen-recurrence-during-follow-up-after-radical-prostatectomy
#19
Martin Andreas Røder, Kasper Drimer Berg, Mathias Dyrberg Loft, Frederik Birkebæk Thomsen, Michelle Ferrari, Sorel Kurbegovic, Helene Charlotte Rytgaard, Lisa Gruschy, Klaus Brasso, Thomas Alexander Gerds, Andreas Kjær, James D Brooks, Peter Iversen
BACKGROUND: It can be challenging to predict the risk of biochemical recurrence (BR) during follow-up after radical prostatectomy (RP) in men who have undetectable prostate-specific antigen (PSA), even years after surgery. OBJECTIVE: To establish and validate a contemporary nomogram that predicts the absolute risk of BR every year after RP in men with undetectable PSA while accounting for competing risks of death. DESIGN, SETTING, AND PARTICIPANTS: A total of 3746 patients from Rigshospitalet (Copenhagen, Denmark) and Stanford Urology (Stanford, CA, USA) who underwent RP between 1995 and 2013 were included...
December 9, 2016: European Urology Focus
https://www.readbyqxmd.com/read/28752596/additional-value-of-the-ratio-of-serum-total-testosterone-to-total-prostate-specific-antigen-in-the-diagnosis-of-prostate-cancer-in-a-chinese-population
#20
L Xu, X Hu, Y Zhu, J Lu, Y Xu, G Wang, J Guo
We investigated whether serum testosterone and testosterone/prostate-specific antigen ratio (T/PSA) might be prostate cancer (PCa) biomarkers. We retrospectively reviewed 92 patients with benign prostatic hyperplasia (BPH) and 164 patients with PCa treated at Zhongshan Hospital, China (April 2012 to November 2013). The BPH and PCa groups had similar serum total testosterone (median, 15.8 versus 16.3 nmol/L).Compared with the BPH group, the PCa group had higher PSA (16.8 versus 5.1 ng/ml) and lower free/total PSA (9...
July 27, 2017: Andrologia
keyword
keyword
68976
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"